See more : iSpecimen Inc. (ISPC) Income Statement Analysis – Financial Results
Complete financial analysis of Aerovate Therapeutics, Inc. (AVTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerovate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fluence Corporation Limited (EMFGF) Income Statement Analysis – Financial Results
- Electric Last Mile Solutions, Inc. (ELMWQ) Income Statement Analysis – Financial Results
- Polycon International Ltd. (POLYCON.BO) Income Statement Analysis – Financial Results
- Sajodongaone Co.,Ltd (008040.KS) Income Statement Analysis – Financial Results
- The Swatch Group AG (UHR.SW) Income Statement Analysis – Financial Results
Aerovate Therapeutics, Inc. (AVTE)
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 96.00K | 68.00K | 15.00K | 1.00K | 0.00 |
| Gross Profit | -96.00K | -68.00K | -15.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.22M | 38.62M | 14.99M | 7.94M | 3.11M |
| General & Administrative | 17.19M | 14.62M | 8.04M | 949.00K | 218.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.19M | 14.62M | 8.04M | 949.00K | 218.00K |
| Other Expenses | 0.00 | -79.00K | -3.00K | -647.00K | 1.00K |
| Operating Expenses | 81.41M | 53.24M | 23.02M | 8.89M | 3.33M |
| Cost & Expenses | 81.41M | 53.24M | 23.02M | 8.89M | 3.33M |
| Interest Income | 5.95M | 1.83M | 65.00K | 75.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 65.00K | 75.00K | 0.00 |
| Depreciation & Amortization | 96.00K | 68.00K | 15.00K | 1.00K | 3.33M |
| EBITDA | -81.31M | -53.17M | -23.01M | -8.89M | 1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.41M | -53.24M | -23.02M | -8.89M | -3.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.94M | 1.75M | 62.00K | -722.00K | 2.00K |
| Income Before Tax | -75.47M | -51.49M | -22.96M | -9.61M | -3.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 56.00K | 25.00K | 3.00K | -572.00K | 1.00K |
| Net Income | -75.52M | -51.51M | -22.96M | -9.04M | -3.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.87 | -2.10 | -0.94 | -0.37 | -0.14 |
| EPS Diluted | -2.87 | -2.10 | -0.94 | -0.37 | -0.14 |
| Weighted Avg Shares Out | 26.33M | 24.47M | 24.41M | 24.41M | 24.41M |
| Weighted Avg Shares Out (Dil) | 26.33M | 24.47M | 24.41M | 24.41M | 24.41M |
SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton
BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE) for potential securities law violations. Investors who have lost money in their Aerovate Therapeutics investment should contact the firm to learn more about...
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to...
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM,...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter...
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the...
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended...
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has...
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a...
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter...
Source: https://incomestatements.info
Category: Stock Reports